Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Non Operating Investment Income (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Non Operating Investment Income for 3 consecutive years, with $196000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Investment Income rose 432.2% to $196000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $668000.0, a 186.64% increase, with the full-year FY2024 number at -$419000.0, down 271.02% from a year prior.
  • Non Operating Investment Income was $196000.0 for Q3 2025 at Mereo BioPharma, up from -$101000.0 in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of $542000.0 in Q1 2023 to a low of -$448000.0 in Q1 2024.
  • A 3-year average of $33700.0 and a median of -$64000.0 in 2024 define the central range for Non Operating Investment Income.
  • Peak YoY movement for Non Operating Investment Income: plummeted 182.66% in 2024, then surged 432.2% in 2025.
  • Mereo BioPharma's Non Operating Investment Income stood at -$195000.0 in 2023, then surged by 180.51% to $157000.0 in 2024, then grew by 24.84% to $196000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Non Operating Investment Income are $196000.0 (Q3 2025), -$101000.0 (Q2 2025), and $416000.0 (Q1 2025).